ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2024, Vol. 33 ›› Issue (5): 401-407.DOI: 10.3969/j.issn.1006-298X.2024.05.001

• 论著 •    下一篇

Plexin-B2及其配体变化在IgA肾病病情分析中的意义

  

  • 出版日期:2024-10-28 发布日期:2024-11-01

Clinical significance of Plexin-B2 and its ligand in IgA nephropathy

  • Online:2024-10-28 Published:2024-11-01

摘要: 目的:基于尿蛋白组学技术,筛选IgA肾病(IgAN)患者表达差异的蛋白,为探索IgAN发病机制和发现潜在生物标志物提供新的线索。
方法:分析IgAN、膜性肾病及健康对照者的尿液蛋白组学数据。将膜性肾病患者和健康者作为对照,筛选出IgAN中差异表达的蛋白。筛选出蛋白Plexin-B2与临床病理指标进行相关性分析。采用酶联免疫吸附试验(ELISA)对血、尿中Plexin-B2及其配体血管生成素(ANG)表达情况进行检测验证并采用免疫组化检测其在肾脏的表达。
结果:与健康对照组相比,质谱法检测的IgAN患者尿液Plexin-B2(uPlexin-B2)表达明显增加,且与总胆固醇(r=0.34,P=0.02)及低密度脂蛋白(r=0.43,P=0.01)呈正相关。uPlexin-B2与节段性肾小球硬化(r=-0.28,P=0.04)呈负相关。ELISA发现IgAN患者uPlexin-B2有升高的趋势。IgAN患者血Ang表达水平明显高于健康对照组(61.97 vs 6.30,P<0.001)。血ANG与肾毛细血管内增殖呈负相关(r=-0.40,P=0.04),与节段性硬化个数呈负相关(r=-0.44,P=0.04)。uPlexin-B2与肾脏球性硬化个数呈负相关(r=-0.95,P=0.01)。Plexin-B2及ANG均在IgAN患者肾小管中高表达。
结论:IgAN患者uPlexin-B2升高。Plexin-B2及ANG与IgAN中肾小球硬化显著相关。ANG在IgAN患者血液中明显升高。本研究可能为发现IgAN的潜在生物标志物提供线索,为探索肾脏病理发病机制提供新思路。


Abstract: Objective:The article was based on urinary proteomics to screen for differentially expressed proteins in IgAN. It may explore the pathogenesis of IgAN and provide new clues for the discovery of potential biomarkers.
Methodology:Urine proteomic data from patients with IgAN and membranous nephropathy, as well as healthy individuals, were analyzed. Patients with membranous nephropathy and healthy individuals were used as controls to screen for differentially expressed proteins in IgAN. The protein Plexin-B2 was to be analyzed for correlation with clinicopathological indicators. The expression of Plexin-B2 and its ligand angiogenin (ANG) in blood and urine was detected and verified by enzyme-linked immunosorbent assay (ELISA) and their expression in renal tissues was detected by immunohistochemistry.
Results:Urinary Plexin-B2 (uPlexin-B2) expression was significantly increased in IgAN patients as detected by mass spectrometry compared to healthy controls. And it was positively correlated with total cholesterol (r=0.34, P=0.02) and LDL (r=0.43, P=0.01). Urinary Plexin-B2 was negatively correlated with segmental glomerulosclerosis (r=-0.28, P=0.04). A trend of elevated uPlexin-B2 in IgAN patients was found by ELISA. The expression level of ANG was significantly higher in the blood of IgAN patients than in the healthy group (61.97 vs. 6.30, P<0.001). ANG in the blood was negatively correlated with endocapillary hypercellularity (r=-0.40, P=0.04) and with the number of segmental sclerosis (r=-0.44, P=0.04). uPlexin-B2 was negatively correlated with the number of glomerulosclerosis (r=-0.95, P=0.01). Both Plexin-B2 and ANG were highly expressed in renal tubules in IgAN.
Conclusion:Urinary Plexin-B2 was increased in patients with IgAN. Plexin-B2 and ANG were significantly associated with glomerulosclerosis in IgAN. Moreover, ANG was notably elevated in the blood of patients with IgAN. The article could provide clues for the discovery of potential biomarkers and provide new insight into the pathogenesis of renal pathology in IgAN.